Considerations for the selection of co-formers in the preparation of co-amorphous formulations

被引:44
|
作者
Yarlagadda, Dani Lakshman [1 ]
Vullendula, Sai Krishna Anand [1 ]
Nair, Athira R. [1 ]
Sree, K. S. Navya [1 ]
Dengale, Swapnil J. [1 ]
Bhat, Krishnamurthy [1 ]
机构
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut Qual Assurance, Manipal 576104, India
关键词
Co-amorphous system; Co-former; Miscibility; Glass forming ability; LLPS; GLPS; Supersaturation; SUPERSATURATED AQUEOUS-SOLUTIONS; SOLID-STATE CHARACTERIZATION; WATER-SOLUBLE DRUGS; IMPROVED PHYSICAL STABILITY; ENHANCED DISSOLUTION RATE; LIQUID PHASE-SEPARATION; GLASS-FORMING ABILITY; ORAL BIOAVAILABILITY; PHYSICOCHEMICAL PROPERTIES; AMINO-ACIDS;
D O I
10.1016/j.ijpharm.2021.120649
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Co-amorphous drug delivery systems are evolving as a credible alternative to amorphous solid dispersions technology. In Co-amorphous systems (CAMs), a drug is stabilized in amorphous form using small molecular weight compounds called as co-formers. A wide variety of small molecular weight co-formers have been leveraged in the preparation of CAMs. The stability and supersaturation potential of prepared co-amorphous phases largely depend on the type of co-former employed in the CAMs. However, the rationality behind the co-former selection in co-amorphous systems is poorly understood and scarcely compiled in the literature. There are various facets to the rational selection of co-former for CAMs. In this context, the present review compiles various factors affecting the co-former selection. The factors have been broadly classified under Thermodynamic, Kinetic and Pharmacokinetic-Pharmacologically relevant parameters. In particular, the importance of Glass transition, Miscibility, Liquid-Liquid phase separation (LLPS), Crystallization inhibition has been deliberated in detail.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Dipeptides as co-formers in co-amorphous systems
    Wu, Wenqi
    Lobmann, Korbinian
    Schnitzkewitz, Jan
    Knuhtsen, Astrid
    Pedersen, Daniel Sejer
    Rades, Thomas
    Grohganz, Holger
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2019, 134 : 68 - 76
  • [2] Predictive identification of co-formers in co-amorphous systems
    Chambers, Luke I.
    Grohganz, Holger
    Palmelund, Henrik
    Lobmann, Korbinian
    Rades, Thomas
    Musa, Osama M.
    Steed, Jonathan W.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 157
  • [3] The influence of co-formers on the dissolution rates of co-amorphous sulfamerazine/excipient systems
    Gniado, Katarzyna
    Lobmann, Korbinian
    Rades, Thomas
    Erxleben, Andrea
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 504 (1-2) : 20 - 26
  • [4] Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems
    Wu, Wenqi
    Ueda, Hiroshi
    Lobmann, Korbinian
    Rades, Thomas
    Grohganz, Holger
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2018, 131 : 25 - 32
  • [5] On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems
    Wu, Wenqi
    Lobmann, Korbinian
    Rades, Thomas
    Grohganz, Holger
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 535 (1-2) : 86 - 94
  • [6] Co-formability, solubility enhancement and stability of olanzapine co-amorphous systems produced with different co-formers
    Bastos, Ana C.
    Santos, Ines A.
    Pinto, Joao F.
    Fernandes, Ana I.
    ANNALS OF MEDICINE, 2021, 53 : S112 - S113
  • [7] Rational excipient selection for co-amorphous formulations
    Korhonen, Ossi
    Pajula, Katja
    Laitinen, Riikka
    EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (04) : 551 - 569
  • [8] Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability
    Liu, Xianzhi
    Shen, Luyan
    Zhou, Lin
    Wu, Wencheng
    Liang, Guang
    Zhao, Yunjie
    Wu, Wenqi
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2024, 200
  • [9] Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers
    Wu, Wenqi
    Grohganz, Holger
    Rades, Thomas
    Loebmann, Korbinian
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 156
  • [10] Implications of phase solubility/miscibility and drug-rich phase formation on the performance of co-amorphous materials: The case of Darunavir co-amorphous materials with Ritonavir and Indomethacin as co-formers
    Shete, Sushant
    Reddy, Sai Charan
    Lakshman, Yarlagadda Dani
    Vullendula, Sai Krishna Anand
    Mehta, Chetan Hasmukh
    Nayak, Usha Yogendra
    Dengale, Swapnil
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 608